Increased use of EMA will improve clinical outcomes in both current and future patients by informing treatment plans and identifying new, potential therapeutic targets as the role of genetics in medicine continues to expand.
Expert John Marshall, MD, reviews the case of a 64-year-old woman who presents with locally advanced pancreatic adenocarcinoma and shares insight on optimal diagnostic workup and molecular analysis techniques.
Pembrolizumab (Keytruda), for example, has induced durable responses in certain subsets of patients with gastric and colorectal cancer (CRC), but many patients still do not respond to this type of therapy.
Immunotherapy has arrived in the gastrointestinal cancer landscape, and while not all patients will benefit from these agents, those who do are likely to have long-lasting responses, explained John L. Marshall, MD.
Pancreatic ductal adenocarcinoma (PDAC) remains the most aggressive malignancy with the lowest 5-year survival rate of all cancers in part owing to the lack of tumor-specific therapy and the rapid metastatic nature of this cancer.